226 related articles for article (PubMed ID: 37124623)
41. Novel cuproptosis-related lncRNAs can predict the prognosis of patients with multiple myeloma.
Chen Y; Tang J; Chen L; Chen J
Transl Cancer Res; 2023 Nov; 12(11):3074-3087. PubMed ID: 38130312
[TBL] [Abstract][Full Text] [Related]
42. A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer.
Xu QT; Wang ZW; Cai MY; Wei JF; Ding Q
Front Pharmacol; 2022; 13():1115608. PubMed ID: 36699089
[No Abstract] [Full Text] [Related]
43. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
[TBL] [Abstract][Full Text] [Related]
44. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Front Genet; 2023; 14():1056000. PubMed ID: 36845390
[No Abstract] [Full Text] [Related]
45. Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer.
Liu X; Zhou L; Gao M; Dong S; Hu Y; Hu C
Front Genet; 2022; 13():989646. PubMed ID: 36204323
[No Abstract] [Full Text] [Related]
46. Comprehensive analysis of cuproptosis-related lncRNAs model in tumor immune microenvironment and prognostic value of cervical cancer.
Wang Q; Xu Y
Front Pharmacol; 2022; 13():1065701. PubMed ID: 36532719
[TBL] [Abstract][Full Text] [Related]
47. Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer.
Jiang W; Du Y; Zhang W; Zhou W
Can J Gastroenterol Hepatol; 2022; 2022():4661929. PubMed ID: 36406148
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive analysis of cuproptosis-related long non-coding RNA signature and personalized therapeutic strategy of breast cancer patients.
Guo Q; Qiu P; Pan K; Lin J
Front Oncol; 2022; 12():1081089. PubMed ID: 36620596
[TBL] [Abstract][Full Text] [Related]
49. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
50. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer.
Du Y; Jiang W; Hou S; Chen Z; Zhou W
Biomed Res Int; 2023; 2023():3419401. PubMed ID: 36714025
[TBL] [Abstract][Full Text] [Related]
51. Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs.
Tu H; Zhang Q; Xue L; Bao J
Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553481
[TBL] [Abstract][Full Text] [Related]
52. Construction of a cuproptosis-associated long non-coding RNA risk prediction model for pancreatic adenocarcinoma based on the TCGA database.
Cui W; Wang Y; Guo J; Zhang Z
Medicine (Baltimore); 2023 Feb; 102(5):e32808. PubMed ID: 36749249
[TBL] [Abstract][Full Text] [Related]
53. A novel risk model based on cuproptosis-related lncRNAs predicted prognosis and indicated immune microenvironment landscape of patients with cutaneous melanoma.
Zhou Y; Shu Q; Fu Z; Wang C; Gu J; Li J; Chen Y; Xie M
Front Genet; 2022; 13():959456. PubMed ID: 35938036
[TBL] [Abstract][Full Text] [Related]
54. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
[TBL] [Abstract][Full Text] [Related]
55. A Prognostic Cuproptosis-Related LncRNA Signature for Colon Adenocarcinoma.
Zhong L; Zhu J; Shu Q; Xu G; He C; Fang L
J Oncol; 2023; 2023():5925935. PubMed ID: 36844874
[TBL] [Abstract][Full Text] [Related]
56. Comprehensive analysis of cuproptosis-related lncRNAs in the prognosis and therapy response of patients with bladder cancer.
Li D; Wu X; Fan X; Cheng C; Li D; Zhang W
Ann Transl Med; 2022 Nov; 10(22):1232. PubMed ID: 36544685
[TBL] [Abstract][Full Text] [Related]
57. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
[TBL] [Abstract][Full Text] [Related]
58. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
[TBL] [Abstract][Full Text] [Related]
59. Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Zhang H; Ning Z; Wang B; Liu Y; Tao B; Zhang G; Liu H; Wang C
Dis Markers; 2023; 2023():7219794. PubMed ID: 36741910
[TBL] [Abstract][Full Text] [Related]
60. [Cuproptosis-related lncRNAs to predict biochemical recurrence of prostate cancer].
Zhao XD; Li Y; Wang ZH; Liu Z; Chen YH; Gu YF; Shang XJ; Xu S
Zhonghua Nan Ke Xue; 2023 Feb; 29(2):120-130. PubMed ID: 37847083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
